LumMed Completes Nearly RMB 100 Million Series A Funding to Advance Breakthrough Minimally Invasive Glaucoma Therapy for Both Open- and Angle-Closure Glaucoma
Purevision Medical
Developer of Ophthalmic Disease Treatment Products
【Viewpoint · Ophthalmology Industry Navigation】
Major Events Monthly Report | Editor's Recommended Article
Winning Atlas· Volume Expansion in Centralized Procurement | Ophthalmic Optometry Column
Recently,Suzhou Purevision Medical Technology Co., LTD. (Abbreviation: Purevision Medical)Announcement CompletedNearly 100 Million RMB in Series A Financing, led by Guangzhou Industrial Investment and Yuekex Financial. The funds will be mainly used forClinical Follow-up, Registration Application, and Industrialization Construction of Core Products。
The company focuses on the Minimally Invasive Glaucoma Surgery (MIGS) field, with its core productAqueFish® Glaucoma Drainage Stent SystemHas entered the special review process for innovative medical devices by the National Medical Products Administration (NMPA) and completed clinical trial enrollment.。
This round of financing comes at a critical juncture in the development of China's glaucoma treatment field. Statistics show that there are over 20 million glaucoma patients in China, with the incidence rate on the rise. Traditional glaucoma surgeries are highly invasive and come with many complications, while minimally invasive glaucoma surgery (MIGS) is becoming the mainstream direction for glaucoma treatment globally. However, MIGS products already on the market in China have long been dominated by foreign brands, primarily designed for open-angle glaucoma, which is more prevalent in Europe and the U.S., offering limited applicability to angle-closure glaucoma, which is more common in Asia.
# Differentiated Design for Asian Populations
Purevision Medical's AqueFish® Glaucoma Drainage Stent System claims to be able toApplicable to both angle-closure and open-angle glaucoma simultaneously, a design feature that reflects the differentiated positioning for the disease spectrum of Asian populations.
From the technical principle analysis,Stent Design for Angle-Closure Glaucoma Needs to Address Special Challenges。
Patients with angle-closure glaucoma have narrow angle structures, making it difficult to place traditional drainage devices, which are also prone to blockage.
The design of AqueFish® stent needs to balance tiny size, precise drainage control, and good tissue compatibility.
The product is designed based on the concept of combining medical and engineering expertise, integrating fluid dynamics simulation with the precision processing of biocompatible materials, and theoretically enabling minimally invasive and precise pressure reduction.
AqueFish® Glaucoma Schlemm's Canal Drainage Stent (Glaucoma Drainage Device)
The product's innovation is also reflected in the choice of materials. The company has developedHigh Oxygen Permeability Silicone MaterialSelected for the major special project "Biomedical Materials Innovation Task" jointly launched by China's Ministry of Industry and Information Technology and the National Medical Products Administration. The biocompatibility, long-term stability, and manufacturing process of materials are key factors affecting product performance, especially in medical scenarios requiring long-term implantation.
From the perspective of clinical progress,The product has entered the special review process for innovative medical devices and completed clinical trial enrollment.. This progress indicates that the product has gained initial recognition from regulatory authorities in terms of technical novelty and clinical demand.
# Market Space for Glaucoma Treatment
Glaucoma, as the world's leading irreversible blinding eye disease, has treatment needs that are both urgent and long-term. The patient base in China is large, and with the aggravation of population aging, the prevalence rate may further increase. However, traditional treatment methods have significant limitations.The development of Minimally Invasive Glaucoma Surgery (MIGS) is precisely aimed at addressing these issues by achieving intraocular pressure control with less trauma.
Challenges of Traditional Surgical TreatmentIncluding issues such as significant trauma, numerous postoperative complications, and a long recovery period, especially for early or mid-stage patients, the trauma-to-benefit ratio of traditional surgery may not be ideal.
Limitations of Existing MIGS ProductsThe design is mainly targeted at European and American populations. There are differences in the distribution of glaucoma types between Asian and European/American populations, with a higher proportion of angle-closure glaucoma in Asians.
Current imported products have limited applicability in this niche area, with significant unmet clinical needs. Purevision Medical’s product development is precisely targeting this market gap.
From the treatment trend, glaucoma treatment is moving towardsEarlier intervention, more minimally invasive, more personalizedThe direction of development. MIGS technology is not only suitable for patients who require surgery but may also extend to earlier stages of intervention. This provides a broader application space for technological innovation.
# The Development Path of High-End Ophthalmic Devices Produced in China
Purevision Medical's financing scale and market response this time reflect the capital market's attention to China-produced high-end ophthalmic device innovation enterprises. The nearly 100-million-yuan Series A financing is considered relatively large in the medical device startup sector, indicating investors' optimism about the development potential of this niche market.
From the perspective of the industry chain, the research and development of high-end ophthalmic devices require deep integration of medical and engineering expertise.Purevision Medical's founding team includes a Ph.D. from Peking University and authoritative ophthalmology experts, ensuring that the products are not only technologically innovative but also meet clinical needs. Especially in the field of surgical instruments, doctors' usage habits and surgical procedures significantly influence product design.
The Construction of Industrialization Capability is the Key to the Success of Innovative ProductsThe financing funds will be used for the construction of production bases, reflecting the company's development phase transitioning from research and development to industrialization. The construction of production bases not only involves hardware investment but also requires the establishment of a comprehensive quality management system and production processes to ensure the consistency and reliability of the products.
From the perspective of market competition,There are multiple imported brands in the MIGS field, but domestically produced products are still in the initial stage.If Purevision Medical successfully gains approval, it will become one of the few MIGS products in China with independent intellectual property rights. However, market competition depends not only on product approval but also on the effectiveness of clinical promotion, doctor acceptance, and long-term follow-up data.
# Company Profile
Purevision Medical is an innovative medical device company that focuses on minimally invasive and precise treatments in ophthalmology. Established in 2020, it was co-founded by Dr. Kan Min from Peking University and authoritative ophthalmology experts. With the core concept of "integration of medicine and engineering, clinically driven," the company specializes in the field of minimally invasive glaucoma surgery (MIGS) and has independently developed one of the few internationally available drainage stent systems that can be used for both angle-closure and open-angle glaucoma, filling a gap in China. In addition, the company's product pipeline covers all stages of glaucoma as well as dry eye and cataract areas, with multiple products already launched in the market.
GOC2025
Ophthalmology Solutions Case
Ophthalmic Instruments Industry Research
Statement
Copyright Statement:The original article "Eye Future" is copyrighted by Beijing Siyu Bot Technology Co., Ltd. Unauthorized reproduction, excerpting, or mirroring on other websites, WeChat Official Accounts, or commercial platforms is prohibited; for authorized reproduction, please contact the backend to obtain permission. This platform reserves the right to pursue legal responsibilities for unauthorized full-text reproduction, content rewriting, or adaptation.
